X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, PaxMedica gains certain suramin research assets to support the submission for the approval of PAX-101 (suramin sodium), specifically for the treatment of African Sleeping Sickness caused by the Trypanosoma brucei rhodesiense parasite.
Lead Product(s): Suramin
Therapeutic Area: Infections and Infectious Diseases Product Name: PAX-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: PaxMedica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 31, 2023
Details:
RLS will use the proceeds to fund a Phase 2 trial of suramin in diuretic resistant Acute Kidney Injury (AKI).
Lead Product(s): Suramin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: REX Health Ventures
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
